RYTM Q3 2017 Earnings — Rhythm Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RYTMRhythm Pharmaceuticals, Inc.

$6B

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$8M

Net Income

-$10M

EPS (Diluted)

$-0.38

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$871,000

Balance Sheet

Total Assets

$35M

Total Liabilities

$6M

Stockholders' Equity

$29M

Cash & Equivalents

$28M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$8M	-$6M	-29.4%
Net Income	-$10M	-$6M	-56.7%